630 related articles for article (PubMed ID: 17164496)
1. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
2. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
Maddineni J; Jeske WP; Baltasar F; Cornelli U; Manoni M; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2006 Jul; 12(3):311-7. PubMed ID: 16959684
[TBL] [Abstract][Full Text] [Related]
3. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
4. Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.
Siddiqui F; Hoppensteadt D; Jeske W; Ramacciotti E; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2024; 30():10760296241247558. PubMed ID: 38656136
[TBL] [Abstract][Full Text] [Related]
5. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
6. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A
Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
10. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
11. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
[TBL] [Abstract][Full Text] [Related]
12. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
Harenberg J
J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
[TBL] [Abstract][Full Text] [Related]
14. Biochemical studies on sulfated lactobionic acid amides.
Klauser RJ; Meinetsberger E; Raake W
Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
[TBL] [Abstract][Full Text] [Related]
16. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density.
Poon MC; Hurst RE; Rives MS
Thromb Haemost; 1982 Apr; 47(2):162-5. PubMed ID: 7101237
[TBL] [Abstract][Full Text] [Related]
17. Neutralisation of heparan sulphate and low molecular weight heparin by protamine.
Hubbard AR; Jennings CA
Thromb Haemost; 1985 Feb; 53(1):86-9. PubMed ID: 3158095
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
Andrassy K; Eschenfelder V; Weber E
Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate.
Racanelli A; Fareed J
Thromb Res; 1992 Nov; 68(3):211-22. PubMed ID: 1471069
[TBL] [Abstract][Full Text] [Related]
20. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
